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Monocytes are circulating precursors for tissue macrophages and dendritic cells (DCs) but 
are not recognized to directly participate in antigen presentation. We developed techniques 
to label mouse monocyte subsets with particulate tracers in vivo. Gr-1lo but not Gr-1hi 
monocytes were stably labeled by intravenous injection of 0.5-𝗍m microspheres. Gr-1hi 
monocytes could be labeled when the microspheres were injected after systemic depletion 
of blood monocytes and spleen macrophages. In this condition, the phagocytic tracer was 
transferred to immature bone marrow monocytes by neutrophils and B cells that fi  rst 
carried the particles to the bone marrow. Moreover, antigens from B cells or proteins 
conjugated to the tracer particles were processed for presentation by monocytes and could 
induce T cell responses in the periphery. Cell-associated antigen taken up by bone marrow 
monocytes was retained intracellularly for presentation of the antigen days later when 
monocyte-derived DCs migrated to lymph nodes or in vitro after differentiation with gran-
ulocyte/macrophage colony-stimulating factor. These data reveal that immature monocytes 
unexpectedly sample antigen from the bone marrow environment and that they can present 
these antigens after they leave the bone marrow.
The online version of this article contains supplemental material.
Monocytes are established precursors for mac-
rophages and DCs. Once monocytes emigrate 
across the endothelial lining of the bloodstream, 
they rapidly begin the process of diff  erentiation 
to one or the other of these terminal pheno-
types (1–3). Thus, as the life cycle of the mono-
cyte is mainly confi  ned to the blood and bone 
marrow, it would seem unlikely that mono-
cytes directly participate in activities like the 
clearance of apoptotic cells or the presentation 
of antigen to T cells other than by serving as 
precursors for the DCs and macrophages that 
perform these tasks. However, it is recognized 
that diff   erent subpopulations of monocytes 
may diff  er in their capacity to develop particu-
lar phenotypes or specializations once recruited 
to a given tissue (4–9).
Macrophages play a major role in clearing 
dead or dying cells (10, 11). DCs also engulf 
apoptotic cells and can cross-present antigens 
from these cells to elicit T cell responses (11). 
Freshly isolated monocytes lack the capacity to 
take up apoptotic cells in vitro (12–14), but 
they may rapidly diff  erentiate and acquire the 
ability to take up apoptotic cells at sites of acute 
infl  ammation, where they appear to be critical 
in removing the mass of dying neutrophils (15). 
Besides sites of acute infl  ammation, the bone 
marrow is another place where many cells con-
tinually undergo apoptosis. There, for example, 
macrophages are involved in clearing the large 
number of B lineage cells that fail to success-
fully recombine genes encoding Ig (16). Fur-
thermore, senescent neutrophils effi   ciently home 
to the bone marrow (17), presumably for clear-
ance by bone marrow macrophages.
The fate of apoptotic cells after engulfment 
by macrophages versus DCs is expected to 
be decidedly diff  erent. DCs initiate immune 
responses and cannot be replaced by macro-
phages for immune priming even for immune 
presentation of microbes like Listeria monocyto-
genes that effi   ciently infect macrophages (18). 
An important factor that enables DCs to pre-
sent epitopes from phagocytized material, ap-
parently including apoptotic cells (19, 20), is 
the poor proteolytic activity they possess in 
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as this property permits the retention of peptides for presen-
tation to T cells. Indeed, DCs can intracellularly retain pep-
tides/antigen for at least 2 d (22), seemingly in waiting for 
conditions that induce their maturation and consequently 
promote the display of the retained peptides on surface 
MHC molecules. Macrophages, on the other hand, robustly 
degrade the phagocytic antigens that they engulf (21) such 
that these antigens are readily destroyed and, therefore, may 
fail to promote T cell priming. The expression of cathepsins, 
the main enzymes responsible for the degradation of proteins 
within intracellular compartments, by blood monocytes mir-
rors their pattern of expression in macrophages qualitatively 
and quantitatively (23). However, in monocytes, cathepsin 
activity is mostly found in endosomes and later becomes 
shifted to lysosomes during maturation to macrophages (23). 
This diff  erence may impact how effi   ciently monocytes de-
grade ingested material because endosomally localized pro-
teolysis may spare peptides for antigen presentation over the 
more robust proteolysis in lysosomes (24).
In this study, we initially set out to develop techniques to 
trace monocyte subsets in vivo that did not rely on adoptive 
transfer. We could stably label Gr-1lo monocytes with a par-
ticulate latex (LX) bead by injection of the beads i.v. How-
ever, the labeling of Gr-1hi monocytes required that we 
introduce LX beads i.v. in the absence of circulating mono-
cytes. In this case, bone marrow monocytes acquired the 
phagocytic label and emerged from the bone marrow as 
the more immature Gr-1hi monocyte subset. Acquisition of the 
label by bone marrow Gr-1hi monocytes resulted from prior 
labeling of other cells, particularly marginal zone B cells and 
neutrophils, that fi  rst carried the particles to the bone marrow 
and transferred them to bone marrow monocytes. Ultimately, 
we show that B cell antigens themselves are acquired by bone 
marrow monocytes, implying that monocytes engulf whole 
cells during the transfer of antigens and that the acquisition of 
this antigen permits presentation of the epitopes much later, 
after monocytes have entered the periphery and further 
  diff  erentiated. These observations unexpectedly reveal that 
monocytes can phagocytize material, including other cells, 
in the bone marrow before entering the circulation. This 
activity can lead to the induction of immune responses to 
the engulfed antigens later in the periphery. We discuss how 
these fi  ndings may also bear on the capacity of monocytes to 
act as Trojan horses for the spread of microorganisms like 
Listeria monocytogenes.
RESULTS
Labeling of blood monocyte subsets with phagocytic tracers
Labeling of Gr-1lo monocytes. Fluorescent LX micro-
spheres can be used to selectively track the migration of 
monocyte-derived DCs from skin to the draining lymph 
node (7, 25). Therefore, we tested whether the systemic 
application of microspheres via i.v. injection would simi-
larly selectively label monocytes in the circulation. Blood 
monocytes coexpress CD115 (macrophage CSF receptor) 
and F4/80 (Fig. 1 A; references 7, 26), and they are divisible 
as three diff  erent subpopulations according to whether they 
express high, intermediate, or low levels of Gr-1 (Ly6C/
G; Fig. 1 A; references 6, 7, 26). Within 4 h after i.v. injec-
tion of LX particles, 1–2% of all cells in the circulation be-
come LX+ (Fig. 1 B). Most LX+ cells were monocytes; 
they   accounted for two thirds of LX+ cells at 4 h (Fig. 1 B) 
after injection and  90% thereafter. Overall,  10–12% of 
blood monocytes were phagocytically labeled using this 
  approach (Fig. 1 B).
In the fi  rst 2 h after LX bead injection, the relative fre-
quency of LX bead uptake among monocyte subsets mir-
rored the overall frequency of the subsets in the whole 
monocyte population, with nearly half of the LX+ cells ex-
pressing high levels of Gr-1 (Fig. 1 C). However, within 4 h 
after injection, these LX+ Gr-1hi monocytes had converted 
to the Gr-1int and Gr-1lo subsets, subsequently resulting in 
only Gr-1lo LX+ monocytes by 24 h (Fig. 1 C). Meanwhile, 
the frequency of the various subsets in the whole monocyte 
fraction remained unaltered (Fig. 1 C). Gr-1lo LX+ mono-
cytes persisted in the circulation for >1 wk, but the percent-
age of LX+ monocytes decreased gradually from nearly 10% 
at day 1 to  5% by day 7 (Fig. 1 D).
Besides the particle-labeled CD115+F4/80+ monocytes 
in the circulation, we observed a large reservoir of LX+ cells 
in the splenic marginal zone (Fig. 1 E, micrograph). Some of 
these cells were CD11bhi macrophages (Fig. 1 E, left fl  ow 
plot), but the majority unexpectedly were marginal zone 
B220+CD19+ B cells (Fig. 1 E, right fl  ow plot). In contrast 
to abundant LX+ B cells in the marginal zone, very few LX+ 
cells were present within B cell follicles (Fig. 1 E, micro-
graph). Although marginal zone B cells in the spleen ac-
quired microspheres, they remained resident therein and 
were not or were only scarcely detected in other examined 
tissue (blood, bone marrow, peripheral lymph nodes, and 
skin) for at least 7 d (not depicted). Thus, i.v. injection of LX 
microspheres stably labels circulating Gr-1lo monocytes, 
whereas some Gr-1hi monocytes were transiently labeled and 
rapidly converted to Gr-1lo monocytes.
Labeling of Gr-1hi monocytes. As previously published, 
monocytes can be rapidly and effi   ciently  (>95%)  elimi-
nated from the circulation by the systemic administration 
of clodronate-loaded liposomes (CLLs; references 7, 26, 
27). In  jection of CLLs i.v. results in the depletion of blood 
monocytes by 18 h (26) accompanied by the full depletion 
of macrophages from the spleen and a transient reduction, 
but not full depletion, of CD115+ monocytes from the 
bone marrow (Fig. 2, A and B; and not depicted).   Marginal 
zone DCs are completely abolished by CLL (28), but white 
pulp DCs are not aff  ected, which is consistent with our ob-
servation that splenic CD11c+ cells were reduced by up to 
50%. As previously shown (26), monocytes began to reap-
pear in blood  40 h after CLL injection (Fig. 2 A).
Injection of LX particles i.v. 18 h after CLL administra-
tion (Fig. 2 C), when monocytes were absent from the blood, 
unexpectedly did not prevent the labeling of blood  monocytes JEM VOL. 203, March 20, 2006  585 
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with the microspheres. Instead, LX+ monocytes still appeared 
in the blood when circulating monocytes were reestablished 
after their CLL-mediated transient depletion (Fig. 2 C). 
  Labeling effi   ciency was 10–15% of the total blood monocyte 
pool (Fig. 2 C). In contrast to the fate of the monocytes that 
took up beads without prior monocyte depletion (Fig. 1), 
LX+ blood monocytes that reappeared after transient mono-
cyte depletion did not rapidly convert to Gr-1lo monocytes; 
instead, they remained Gr-1hi for  7 d, when they then be-
gan to convert into Gr-1int and Gr-1lo subsets (Fig. 2 C). 
Their frequency in blood was only slightly reduced over 
a 7-d period (Fig. 2 C, bar graph). Thus, this method that in-
volves an initial monocyte depletion step leads to stable label-
ing of Gr-1hi blood monocytes, which is in contrast to the 
aforementioned protocol that leads to the labeling of Gr-1lo 
monocytes (Fig. 1).
Figure 1.  Labeling of Gr-1lo monocytes by i.v. LX particles. 
(A) Monocytes were identifi  ed as low SSC CD115+ F4/80+ live cells, and 
subsets were defi  ned by surface Gr-1 levels (lo, low; int, intermediate; 
hi, high). (B) Blood analysis 4 h after i.v. LX bead injection. Gates on total 
live cells, LX+ cells, or monocytes are shown. Data are representative of 
>20 experiments. (C) Short-term time course of the Gr-1 phenotype of 
LX+ monocytes (monos) or all monocytes after i.v. administration of LX 
beads in the blood (n = 6 at each time point). (D) LX labeling effi  ciency 
of Gr-1lo monocytes expressed as the percentage of all monocytes. 
Data are the means ± SEM (error bars) of >10 animals per time point. 
(E) Analysis of spleen after i.v. injection of LX particles. FACS analysis 4 h 
after LX   injection identifi  es most LX+ cells in the spleen as B220+CD19+ 
B cells and fewer CD11bhi macrophages. (right) Sections of spleen 1 d 
after i.v. LX administration stained for CD11b (red) show LX beads 
(green) in the marginal zone (arrow) but not in white pulp (asterisk). 
Bar, 100 μm.586   MONOCYTES SAMPLE ANTIGENS IN BONE MARROW | Tacke et al.
LX particle transfer to bone marrow monocytes from B cells 
and neutrophils
We next wondered how monocytes became labeled with par-
ticles after CLL depletion because monocytes were not present 
in the circulation when LX beads were injected therein. Few 
free particles were observed in blood at the time when mono-
cytes began to return after depletion (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20052119/DC1), so it 
seemed unlikely that the nascent monocytes would   encounter 
free particles during their labeling. Indeed, our investigation 
Figure 2.  Labeling of Gr-1hi monocytes by i.v. clodronate liposomes 
followed by LX particle injection. (A) Flow cytometric evaluation of 
blood monocytes. By 18 h after i.v. injection of CLLs (clo-lip), >95% of all 
blood monocytes are depleted from the circulation. 1 d later (42 h after 
clo-lip), monocytes reappear in the blood (right plot). (B) Flow cytometric 
evaluation monitored the presence of monocytes in blood and bone 
  marrow at various time points after CLLs were injected i.v. The line graph 
illustrates the degree of depletion in blood and bone marrow through 8 d. 
Results are expressed as the percent frequency of monocytes ± SEM 
(error bars) compared with their starting baselines in blood and bone 
marrow (BM). (C) Injection schedule for the labeling of Gr-1hi monocytes 
in circulation is depicted. The labeling of returning blood monocytes with 
LX at day 1 is shown (dot plot). Histograms reveal the intensity of Gr-1 on 
the LX+ returning monocytes, and the bar graph indicates the LX labeling 
effi  ciency of Gr-1hi blood monocytes (mean ± SEM). More than eight 
animals were examined and showed similar results per time point; 
  individual animals are shown.JEM VOL. 203, March 20, 2006  587 
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into this question, detailed in this section, illustrated that 
the particles were transferred via other cell types that fi  rst 
  acquired them in the absence of monocytes. 
Fig. 2 delineated our detection of LX+ monocytes at the 
time points (day 1 and beyond) when monocytes returned to 
blood after depletion. When we examined blood after LX 
Figure 3.  Labeling of blood B cells and neutrophils during mono-
cyte depletion. (A) The injection scheme, as depicted, was to administer 
CLLs and, 18 h later, when monocytes were depleted, to inject LX beads i.v. 
The blood was examined for LX+ cells 4 h thereafter. LX+ cells at this time 
point were CD115− cells. (B) The LX+ CD115− blood cells during monocyte 
depletion (4 h after LX administration; see injection scheme in A) was 
comprised of two populations: small lymphocytes (arrowheads in cyto-
spin) that stain positive for B220, CD19, and anti-FITC and large neutro-
phils (arrow in cytospin) that stain positive for CD11b and Gr-1 and 
negative for anti-FITC. Red lines in each profi  le reveal staining for these 
molecules; green lines reveal staining with isotype-matched control 
mAbs. Data are representative of at least six mice analyzed individually 
per condition. (C) The bone marrow in mice subjected to the injection 
scheme in A and examined 4 h after LX was administered i.v. shows popu-
lations with similar profi  les as in the blood. Gates of LX+ cells in bone 
marrow reveal small cells with low SSC (gated blue in the FSC/SSC plot) 
and larger cells with high side scatter (gated red in the FSC/SSC plot). 
Histograms show staining patterns of these populations in the same color 
as the corresponding gate. (D) The occurrence of apoptotic cells in the 
bone marrow was monitored by annexin V staining in mice injected with 
CLLs followed by LX particles (as per the injection scheme in A). The bone 
marrow was examined 1 d after LX beads were administered i.v. The gray 
histogram represents gates on all cells, the blue line represents gating on 
small LX+ cells (B cells; blue gate in C), and the red line represents gating 
on large LX+ cells (neutrophils; red gate in C). Percentage of annexin 
V–positive cells (bar) is shown.588   MONOCYTES SAMPLE ANTIGENS IN BONE MARROW | Tacke et al.
particle   administration but before CD115+ monocytes reap-
peared, we observed the presence of LX particles in CD115− 
blood cells (Fig. 3 A). When we sampled blood 4 h after the 
i.v. administration of LX beads, 20–25% of LX+ cells in the 
circulation were neutrophils, as indicated by their high for-
ward scatter (FSC)/SSC profi  le (Fig. 3 B, dot plot), typical 
nuclear morphology (Fig. 3 B, arrow in photomicrograph), 
positive reactivity with mAbs to CD11b, Gr-1, and CD62L, 
and negative reactivity with mAbs to CD115, CD3, CD4, 
CD8, B220, CD19, I-Ab (MHC-II), DX5, and NK1.1 (Fig. 
3 B, histograms; and not depicted). The LX particles associ-
ated with these neutrophils had been phagocytically internal-
ized, as they were inaccessible to reactivity with anti-FITC 
mAb (Fig. 3 B, histogram).
In addition to labeled neutrophils, between 50–60% of 
the blood LX+ cells found in the absence of monocytes were 
Figure 4.  Mobilization of LX+ neutrophils and B cells from the 
spleen to the bone marrow leads to robust monocyte labeling. (A) LX 
beads were injected i.v. Then, 8 h later, some mice received CLLs i.v. (middle 
dot plot). The blood was analyzed 12 h later, 20 h after the administration 
of LX beads, and at several time points thereafter. At the 12-h time point, 
most LX+ cells seen in the group of mice receiving CLLs were CD115− cells 
with the high FSC/SSC profi  le of neutrophils (middle and right dot plots). 
A comparison with mice receiving no liposomes, only LX i.v., is shown in 
the left dot plot. (B) A time course depicts the fraction of LX+ cells among 
total bone marrow cells that were CD115− (mostly neutrophils and B cells) 
and CD115+Gr-1hi monocytes from 4 h to 2 d after the administration of 
CLL. Error bars represent SEM. (C) Bone marrow was analyzed 16 h after 
liposome administration. Monocytes were identifi  ed by double staining for 
F4/80 and CD115, and the degree to which this population was LX+ was 
assessed (right plots). Comparison was made with mice that received only 
LX beads without CLL (left plots). (D) Analysis of the monocyte population 
in blood at day 2 or later after CLLs were administered. All data are repre-
sentative of more than six mice per condition.JEM VOL. 203, March 20, 2006  589 
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B cells, as determined by their low FSC/SSC profi  le (Fig. 3 B, 
dot plot), typical lymphocytic morphology (Fig. 3 B, arrow-
heads in photomicrograph), positive reactivity with mAbs to 
B220, CD19, I-Ab, and CD62L, and negative reactivity with 
mAbs to CD115, F4/80, Gr-1, CD11b, CD3, CD4, CD8, 
DX5, and NK1.1 (Fig. 3 B, histograms; and not depicted). In 
contrast to the neutrophils, the LX particles associated with B 
cells were present on the cell surface and were not internal-
ized because most of these cells reacted positively with anti-
FITC mAb (Fig. 3 B).
Recalling that even in the continuous presence of mono-
cytes, a major reservoir of LX+ CD19+B220+ marginal zone 
B cells after the injection of particles was sequestered in the 
spleen (Fig. 1), it seemed likely that the depletion of marginal 
zone splenic macrophages by CLLs initiated mobilization of 
marginal zone B cells to the blood. Marginal zone macro-
phages normally interact with marginal zone B cells (29), so 
it is reasonable that when LX beads are administered in the 
absence of monocytes and marginal zone macrophages, some 
LX+ marginal zone B cells become diverted to the circula-
tion. Besides being present in blood, the two populations of 
CD115− LX+ cells also homed to bone marrow (Fig. 3 C). 
LX+ neutrophils were identifi  ed by their FSC/SSC profi  le 
and because of their high Gr-1 and CD11b expression (Fig. 
3 C); B cells were CD19+B220+ (Fig. 3 C). The presence of 
a few CD19+ cells in the high SSC gate (gate 1; Fig. 3 C) 
suggests that some B cells may associate with neutrophils. 
LX+ B cells mainly bearing only a single bead per cell dis-
persed systemically. Besides traffi   cking to bone marrow, 
they additionally homed to lymph nodes (unpublished data). 
  Neutrophils arriving in the bone marrow were clearly under-
going apoptosis, as a substantial fraction of them stained posi-
tively with annexin V within the fi  rst day after their arrival 
(Fig. 3 D). We observed only a few annexin V+ LX+ B cells, 
so it remains unclear how many of the B cells were undergo-
ing apoptosis shortly after arrival in the bone marrow. None-
theless, the appearance of LX+ B cells in the bone marrow, 
like neutrophils, was transient. By day 2 after the appearance 
of these populations in the bone marrow, the frequency of 
these cells was reduced in the bone marrow, as the appear-
ance of LX+ monocytes began instead to emerge in blood 
and bone marrow (Figs. 2 and 4). Therefore, the survival of 
LX+ neutrophils and B cells in the bone marrow is likely 
  relatively brief.
To further test whether it was the dispersion of numer-
ous LX+ neutrophils and B cells to the blood or bone mar-
row that led to the delivery of particles to the Gr-1hi 
monocyte population, we inversed the order of monocyte 
depletion and particle labeling such that particle-bearing cells 
were fi  rst sequestered in the spleen before potentially be-
coming mobilized by the introduction of CLLs. Thus, LX 
Figure 5.  Adoptive transfer of LX+ CD45.2+ B cells and neutrophils 
into CD45.1+ recipient mice. (A) For the isolation of B cells for adoptive 
transfer, donor mice were treated fi  rst with CLL and then with LX beads i.v 
as described in Materials and methods. B220+ cells were positively se-
lected using magnetic cell sorting beads, and 15–20% of these B cells 
were LX+. Cells enriched with LX+ neutrophils (CD11b+ CD115− cells with 
high SSC) were prepared by incubating total bone marrow cells ex vivo 
with LX beads. A minor population (<3% of total cells) of this cell 
  preparation were LX+ monocytes, shown by CD115 staining (right plot). 
(B) Bone marrow was analyzed 2 d after adoptive transfer, when blood 
monocytes were beginning to return. CD45.2+ transferred cells were 
  present when either labeled B cells (left) or neutrophils (right) were trans-
ferred. (C and D) In the circulation of recipient mice that received adop-
tively transferred LX+ B cells (C) or cell preparations enriched in 
neutrophils (D) 18 h after the administration of CLL, CD115+ monocytes 
were observed that became LX+ (left), were Gr-1hi (black lines, middle; 
gray line identifi  es Gr-1lo control staining), and were CD45.1+ (right, 
black lines; gray lines represent negative control staining). The intensity of 
Gr-1 staining on Gr-1hi cells varies from C because of the use of a differ-
ent anti–Gr-1 conjugate. In each experimental design, at least six mice 
were recipients of adoptively transferred cells (three experiments con-
ducted in duplicate), and each showed similar outcomes.590   MONOCYTES SAMPLE ANTIGENS IN BONE MARROW | Tacke et al.
particles were injected i.v. fi  rst, and CLLs were injected 8 h 
later (Fig. 4 A, schematic depiction of injection scheme). 
The number of LX+ cells in the circulation was dramatically 
increased by this approach compared with the injection of 
LX alone (Fig. 4 A), such that 20% of the leukocytes in 
blood were LX+ 12 h after CLL injection compared with 
only 0.8% ( 10% of monocytes) of leukocytes in the blood 
of mice that received LX beads i.v. but not CLLs (Fig. 4 A). 
In this protocol, as in Fig. 3, the LX+ cells were again 
B220+CD115− B cells and CD11b+Gr-1+CD115− neutro-
phils, but the majority by this protocol were neutrophils 
(FSC/SSC profi  le; Fig. 4 A and not depicted). In bone mar-
row, by 4 h after the dispersion of LX+ cells from the spleen 
using CLL, >2% of the bone marrow was LX+, and nearly 
all of these cells were CD115− B cells and neutrophils (Fig. 
4 B and not depicted). By 12 h, LX+ cells continued to 
  increase in the bone marrow, and a greater fraction was 
CD115+. CD115+ cells accounted for an increasingly greater 
proportion of the LX+ cells in the bone marrow at 16 h and 
day 2, as the frequency of LX+ CD115− cells declined by 
day 2, and the LX+ CD115+ cells in the bone marrow 
reached an equilibrium (Fig. 4 B). 
At 16 h after CLL injection,  50% of the bone marrow 
CD115+ cells were LX+ (Fig. 4 C). In contrast, only  3% of 
the CD115+ bone marrow cells were LX+ at this same time 
point when LX beads were administered i.v. in the absence 
of blood monocyte depletion (CLL treatment). During the 
fi  rst 24 h after CLL administration, there were no circulating 
monocytes as a result of the depletion mediated by CLLs. 
However, at day 2 (40 h after CLL injection), 35% of the re-
turning monocytes in blood were LX+ and Gr-1hi (Fig. 4 D), 
mirroring the high labeling of bone marrow precursors at 
day 1. The fraction of LX-labeled monocytes remained high 
for at least several days, with 25% of blood monocytes being 
LX+ at day 3 and 12% at day 6 (Fig. 4 D).
These experiments were consistent with the possibility 
that monocyte precursors in the bone marrow may have 
  engulfed particle-bearing B cells and neutrophils that homed 
to the bone marrow after release from the spleen, leading to 
their own labeling with LX before entering the circulation 
Figure 6.  Effect of B cell defi  ciency and PT on the transfer of LX 
to bone marrow monocytes. (A) C57BL/6 WT (white bars) and B cell–
defi  cient μMT mice (black bars) were treated i.v. with LX particles fol-
lowed by CLLs as diagramed in the schematic. The percentage of 
CD115+ monocytes that were LX+ in bone marrow and blood is de-
picted. Results are expressed as means ± SEM (error bars); differences 
between WT and μMT mice at most time points are signifi  cant 
(*, P < 0.05 using a t test). (B) LX beads were administered to mice, 
and mice received CLL i.v. 8 h later along with PT or PBS. Bone marrow 
was examined at 16 h to assess the impact of PT treatment on the 
  acquisition of LX by monocytes. Data are representative of three mice 
in each condition, all with similar outcomes. (C) Mice received PT or 
PBS i.v. followed by LX beads i.v. 2 h later, and bone marrow was 
  examined after 24 h for LX particle uptake by monocytes. Data 
shown are representative of three mice in each condition, all with 
similar outcomes.JEM VOL. 203, March 20, 2006  591 
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as Gr-1hi monocytes. To further explore whether B cells and 
neutrophils that acquire LX microspheres during monocyte 
depletion might transfer particles to immature monocytes in 
the circulation or possibly to bone marrow monocyte pre-
cursors, we adoptively transferred LX+ B220+ B cells (Fig. 5 
A) and/or cell preparations enriched with CD11b+CD115− 
LX+ neutrophils (Fig. 5 A) from CD45.2+ (Ly5.2) donors 
into CD45.1+ (Ly5.1) transgenic mice that had earlier re-
ceived CLLs. CD45.2+ LX+ B cells and neutrophils were 
observed to home to the bone marrow (Fig. 5 B); the frac-
tions of CD45.2+ cells recovered in the bone marrow that 
were also LX+ were 15 and 5%, respectively. After the trans-
fer of either cell type and recovery of blood monocyte pools, 
LX+ Gr-1hi CD45.1+CD45.2− monocytes appeared in the 
circulation (Fig. 5, C and D), although the effi   ciency  of 
monocyte labeling with adoptively transferred cells (<1% of 
all monocytes) was reduced compared with the labeling that 
occurs endogenously (Figs. 2–4). These data indicate that 
monocyte labeling with LX indeed occurs through the 
transfer of LX beads by other cells, in this case by neutro-
phils or B cells.
Kinetic studies revealed that bone marrow monocytes 
were substantially LX+ by 16 h after CLLs were administered 
to mice that were previously treated to label LX+ B cells and 
other cells in the spleen (Fig. 6 A, injection   schematic). At 
16 h, mobilized LX+ B cells and neutrophils have already 
reached the bone marrow at least several hours earlier (Fig. 
4 B) and are undergoing transfer to bone marrow mono-
cytes by this time (Figs. 4 B and 6 A, left bar graph). In mice 
  lacking B cells (μMT mice), the labeling effi   ciency of bone 
Figure 7.  Antigen presentation of cellular proteins from trans-
ferred allogeneic B cells to monocytes. (A) I-Ad+ B cells were isolated 
from spleen and lymph nodes of BALB/c mice and injected i.v. into mono-
cyte-depleted C57BL/6 mice 18 h after treatment with CLLs as shown in 
the schematic. Monocyte-depleted mice that did not receive BALB/c 
B cells served as controls. The presence of I-Ad+ B cells was analyzed in 
blood, bone marrow, and spleen 4 h and 1 d after B cell transfer. Cells 
with a low FSC/SSC profi  le were gated to focus analysis on lymphocytes, 
and the percentage of CD19+IAd+ lymphocytes was determined. Each plot 
shows the mean + SD of at least three mice studied per condition. 
(B) Histograms show Y-Ae expression on blood monocytes at days 1 and 3 
(gray histogram, controls; black line, BALB/c B cell transfer). Six animals 
per condition were studied in three independent experiments. (C) Whole 
blood cells were prepared 3 d after BALB/c cell transfer i.v., and washed 
leukocytes were cultured for 2 d in the presence of GM-CSF to promote 
the differentiation of monocytes toward a DC phenotype. Y-Ae (left) and 
CD11c (right) expression by monocytes was examined after BALB/c B cell 
transfer before (dark gray line) and after (black line) culture; gray histo-
gram, control monocytes from mice not receiving transferred B cells after 
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marrow monocytes was somewhat reduced, which is consis-
tent with the possibility that B cell migration to bone mar-
row is necessary for optimal monocyte labeling (Fig. 6 A). 
This reduced labeling of bone marrow monocytes in μMT 
mice was accompanied by a subsequent reduction of blood 
monocyte labeling after monocytes reappeared in the circu-
lation at day 2 (Fig. 6 A). Therefore, we next examined the 
eff  ect of blocking the traffi   cking of both neutrophils and B 
cells to the bone marrow. Both B cells and neutrophils at 
least partly use the Gi protein–coupled chemokine receptor 
CXCR4 to home to the bone marrow (17, 30). Thus, we 
determined whether pertussis toxin (PT) would impair the 
postulated cell-mediated transfer of particles to bone marrow 
monocytes. PT-treated mice showed blood neutrophilia and 
increased numbers of neutrophils in the spleen but reduced 
bone marrow neutrophils (unpublished data). When PT was 
injected i.v. during the periods when CLLs and LX were 
administered, the labeling of bone marrow monocytes with 
LX was dramatically reduced compared with PBS-injected 
controls (Fig. 6 B). Instead, LX+ neutrophils were abun-
dantly found in the blood and spleen (not depicted). The 
relatively smaller number of bone marrow monocytes that 
acquires LX in the bone marrow when CLL is not used to 
mobilize neutrophils and B cells from spleen (Fig. 4 C, LX 
i.v.) was unaff  ected by the prior administration of PT (Fig. 6 
C), indicating that PT did not directly aff  ect the phagocytic 
activity of bone marrow monocytes. Therefore, the reduced 
labeling of bone marrow monocytes in the presence of PT 
after CLL treatment supports the conclusion that the degree 
of homing of LX+ neutrophils and B cells to the bone mar-
row directly aff  ects how effi   ciently Gr-1hi monocytes be-
come labeled with LX. These data collectively show that B 
cells or neutrophils pass particulate antigens to monocytes 
and illustrate that the bone marrow is the major site of par-
ticulate antigen transfer.
Processing and presentation of transferred antigens
Because neutrophils phagocytized LX particles and car-
ried them intracellularly, the transfer of neutrophil-associated 
  particles to monocytes suggests that the monocytes engulfed 
the neutrophil after its arrival into the bone marrow. How-
ever, because B cells carried the particles on their surface, it 
mice per group. (C) OVA-LX–labeled monocytes (splenic DCs were posi-
tive controls) were isolated from bone marrow and injected intrader-
mally into the back skin and front footpad of MHC-II−/− mice, which 
had received CFSE-labeled OT-II cells. Proliferation of CFSE-labeled OT-II 
cells was assessed at day 6. A gate was drawn around CFSE-labeled 
T cells in each mouse. The number accompanying the left side of the 
box indicates percent proliferated CFSE-labeled T cells; the number 
marking the right side of the box indicates the fraction of CFSE-labeled 
T cells that did not proliferate.
Figure 8.  Antigen presentation by Gr-1hi– and Gr-1lo–labeled 
monocytes and induction of T cell proliferation in vivo. (A) CD4+ 
OT-II cells pooled from spleen and lymph nodes by positive selection for 
CD4 expression were labeled with CFSE and injected into CLL-treated 
C57BL/6 wt mice (left) or B cell–defi  cient μMT mice (right) that had also 
received either plain (not conjugated) LX beads or OVA-conjugated LX 
beads. (B) A similar experimental design was performed except that 
mice were not treated with CLL, such that Gr-1lo monocytes became LX+. 
(A and B) These data are representative of three experiments with two JEM VOL. 203, March 20, 2006  593 
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was not clear whether the transfer of particles to monocytes 
from B cells involved the engulfment of dying B cells. To as-
sess this possibility defi  nitively and to determine whether any 
processed cell antigen was routed by the monocyte for dis-
play to T cells, we determined whether the adoptive transfer 
of BALB/c B cells into C57BL/6 hosts would lead to reactiv-
ity of the monocytes with the Y-Ae antibody. This mAb re-
acts with a peptide derived from I-Eα of BALB/c donor cells 
presented in the context of I-Ab (19, 31).
BALB/c B cells were prepared by minimagnetic cell sort-
ing separation, and 5 million were transferred to CLL-treated 
C57BL/6 recipients i.v. Although it would be expected that 
the majority of these B cells would die spontaneously or in 
response to NK cell–mediated killing after transfer, we ob-
served that the traffi   cking of allogeneic B cells was strikingly 
similar to the mobilization of LX+ B cells to the bone mar-
row (Fig. 3). 4 h after transfer, BALB/c B cells, identifi  ed as 
CD19+ IAd+ cells, were found in the blood, bone marrow, 
and spleen (Fig. 7 A). By 24 h, transferred cells were scarcely 
detectable in the blood, were greatly reduced in the bone 
marrow, but remained detectable in the spleen (Fig. 7 A).
1 and 3 d later, we analyzed whether any of the mono-
cytes expressed the Y-Ae epitope, which is indicative of pro-
cessing and presenting BALB/c B cells. To control for the 
specifi   city of the Y-Ae mAb, we stained monocytes from 
C57BL/6 mice that did not receive adoptively transferred 
BALB/c cells. 5–10% of monocytes, all from the Gr-1hi sub-
set in CLL-treated mice, reacted specifi  cally with the Y-Ae 
mAb (Fig. 7 B). The intensity with which these cells reacted 
with the Y-Ae mAb increased after the monocytes were cul-
tured for 2 d in the presence of GM-CSF to induce CD11c 
and direct their diff  erentiation toward a DC phenotype (Fig. 
7 C; reference 32). The increased staining for Y-Ae on the cell 
surface of Y-Ae–positive monocytes indicates that a depot of 
antigen can be maintained intracellularly for up to 2 d and 
later presented more effi   ciently on the surface as diff  erentia-
tion proceeds.
Therefore, we investigated whether monocytes that 
phagocytize cell-associated antigens in the bone marrow 
would trigger T cell responses in the bone marrow or other 
lymphoid tissues. We measured the proliferation of CFSE-
labeled OT-II T cells in which the TCR of CD4+ cells is 
restricted to OVA peptide. We covalently coupled OVA 
protein to carboxylate-modifi  ed red fl  uorescent particles for 
delivery fi  rst to neutrophils and B cells, which, in turn, would 
transfer the particles to monocytes. Because the presentation 
of antigen by B cells themselves would confound our analy-
sis, all experiments were performed in B cell–defi  cient μMT 
mice alongside WT mice. Red fl  uorescent particles (OVA 
coupled or plain) labeled monocytes just as well and as spe-
cifi  cally as FITC-labeled LX particles used in the previous 
experiments (unpublished data).
Plain (no OVA) LX particles or OVA-coupled LX parti-
cles were injected in mice initially depleted of monocytes to 
set up labeling of Gr-1hi monocytes by cell transfer. Particle-
bearing monocytes were found to express I-Ab, which may 
become up-regulated in response to the particle itself. CFSE-
labeled CD4+ T cells from OT-II mice were injected i.v. 1 d 
later. 3 d after the adoptive transfer of T cells in OVA-  coupled 
LX-treated mice, proliferation was evident among the OT-II 
T cells recovered from the blood, lymph nodes, and spleen 
but not from the bone marrow. Proliferation did not occur in 
mice that received plain (no OVA) LX particles (Fig. 8 A). 
Mice injected with OVA protein i.p. served as a positive 
control (not depicted).
When the same OVA-conjugated particles were engulfed 
by Gr-1lo monocytes using the protocol shown in Fig. 1, 
OT-II T cell proliferation was evident when we sampled 
blood, lymph nodes, or spleen but not bone marrow. Thus, 
targeting of antigen to either monocyte subset led to the acti-
vation of antigen-specifi   c T cell responses (representative 
data shown for the spleen in Fig. 8 B).
We wanted to be sure that T cell proliferation was caused 
by OVA antigen delivered to bone marrow monocytes that 
later matured to present the antigen in peripheral lymphoid 
tissues. Thus, we repeated experiments assessing T cell pro-
liferation in mice that received adoptively transferred popu-
lations of monocytes that had engulfed LX+ cells in the 
bone marrow. Bone marrow monocytes from mice injected 
with OVA-conjugated particles and CLLs were transferred 
into MHC-II–defi  cient recipients that had been preinjected 
with CFSE-labeled OT-II T cells. MHC-II−/− recipient 
mice were used to prevent cross-presentation from possibly 
dying transferred monocytes to the CD4 T cells. Proliferat-
ing T cells were evident 6 d later in lymphoid organs and 
blood (Fig. 8 C).
DISCUSSION
In this study, we report methods to selectively label mouse 
monocyte subsets by injecting particles for phagocytosis i.v. 
Under conditions in which particles are administered with-
out further perturbations to the mouse, monocytes in the 
circulation are the major population labeled, where  10% 
of monocytes in the blood engulf the microspheres. Initially, 
this fraction of labeled monocytes is comprised of both 
Gr-1hi and Gr-1lo monocyte subsets, but, within 24 h, all of 
the microsphere-bearing monocytes in the blood are part of 
the Gr-1lo subset. Gr-1hi monocytes serve as the precursors 
for Gr-1lo monocytes (7, 26), but it remains unclear what 
events or molecules trigger the conversion from the Gr-1hi 
to the Gr-1lo phenotype. It appears that administration of 
the microspheres themselves promotes rapid conversion. 
A slower rate of conversion is observed when spontaneous 
conversion of Gr-1hi monocytes is allowed to occur (e.g., 
after transient clodronate liposome-mediated depletion; 
  references 7, 26).
The intention of developing this method was to apply the 
technique in tracing monocyte subset recruitment and dif-
ferentiation. The administration of FITC-LX microspheres 
stably labeled only the Gr-1lo monocytes, which limited 
the application of this technique to tracing only the fate of 
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method—the injection of LX microspheres i.v.—could be 
used to selectively label blood Gr-1hi monocytes when the 
administration of particles was coupled with protocols to de-
plete monocytes. In this case, the new monocytes that en-
tered the circulation after their depletion are uniformly of the 
Gr-1hi subset, and, again, at least 10% of them carried LX. 
Thus, these two protocols involving i.v. administration of 
LX microspheres permit distinct tracking of the fate of mon-
ocytes derived from diff  erent subsets over time. The tech-
nique is readily applicable to protocols that aim to trace the 
diff  erentiation and migratory fate of monocytes in vivo, and 
we have already used the approach in a study that reveals that 
Gr-1hi monocytes develop into Langerhans cells after skin in-
jury (9). Importantly, phagocytosis of the labeled particles, at 
least in the small quantities that are taken up in our protocol, 
does not alter the traffi   cking capacity of the monocytes (un-
published data).
It was particularly unexpected that monocytes (Gr-1hi) 
appeared in blood labeled with i.v.-administered micro-
spheres under circumstances in which the particles were ini-
tially injected into mice that had been depleted of monocytes. 
As we explored how this labeling occurred, it became appar-
ent that bone marrow monocytes (or promonocytes) were 
engulfi  ng other cells, namely B cells and neutrophils, that 
carried the particles to the bone marrow in the fi  rst place. 
  Indeed, although monocytes were the major cell type labeled 
with microspheres when they were injected into unperturbed 
mice, a substantial fraction of the label was also associated 
with various cells in the spleen that did not substantially parti-
tion in the blood: macrophages, neutrophils, and, surpris-
ingly, marginal zone B cells. Macrophages and neutrophils 
clearly engulfed the microspheres they associated with, as 
these spheres were inaccessible to a mAb against FITC (the 
fl  uor incorporated in the microspheres) applied to the cell 
surface. In contrast, whereas B cells stably associated with 
particles and could carry them into distal locations like bone 
marrow and lymph nodes when they left the spleen, they 
failed to internalize the particles.
We observed that neutrophils and B cells were carrying 
the particles to the bone marrow and that detection of these 
cells with the particles dissipated at the same time we began 
to observe Gr-1hi monocytes in the bone marrow that had 
internalized beads. As a result, we wondered whether the 
labeled monocytes may be engulfi  ng the incoming neutro-
phils and B cells. Neutrophils that migrate to the bone mar-
row after having been in the periphery are typically senescent 
(17). Considering these recent fi  ndings, it was not surprising 
that the neutrophils likely die in the bone marrow. First, we 
wanted to be sure that acquisition of the particles required 
the migration of neutrophils and B cells to the bone mar-
row as opposed to other possibilities like accumulation of 
free beads in the bone marrow. Using the broadly eff  ective 
inhibitor of migration PT, we observed that the labeling of 
bone marrow monocytes was greatly impeded in the pres-
ence of PT, indicating that the process by which the label 
was transferred was not passive, as would be the case with 
free beads. Adoptive transfer experiments furthermore il-
lustrated that the transfer of congenic CD45.2+ neutrophils 
or B cells bearing particles into CD45.1+ hosts resulted in 
CD45.1+ monocytes carrying particles in the circulation. 
Thus, there was a clear transfer of particles fi  rst borne by 
neutrophils or B cells into monocytes. Finally, the transfer 
of BALB/c B cells into C57BL/6 hosts revealed monocytes 
that carried an epitope derived from B cells and recognized 
by the Y-Ae mAb, indicating that more than just the particle 
was transferred to the monocytes. Indeed, some monocytes 
must be, to some extent, internalizing B cells themselves. 
However, we cannot eliminate the possibility (and indeed 
consider it likely) that some of the transferred particles are 
dropped from the surface of B cells after their arrival in the 
bone marrow and are engulfed by the monocytes thereafter. 
A similar outcome of robust monocyte labeling occurs in 
the absence of B cells (μMT mice) when neutrophils are 
the major transferring cell, and because the neutrophils fully 
phagocytize the particles, it is very likely that in this sce-
nario monocytes acquire the particles essentially completely 
through the uptake of senescent neutrophils.
Considering that neutrophils, but not B cells, internalized 
the particles and that neutrophils are known to die in the 
bone marrow (17), the observation that neutrophils transfer 
antigens to monocytes is likely more physiologically relevant 
than the transfer of particles by marginal zone B cells. None-
theless, it is likely that any cell that dies in the bone marrow, 
either after developing in the bone marrow or after migrating 
there, could be acquired by monocytes as shown herein for 
the labeled cells that we trace. It is becoming increasingly 
clear that a range of leukocytes migrate from blood back to 
bone marrow under certain circumstances (33).
The sequence of events that leads to the spread of in-
fection with Listeria monocytogenes is becoming increasingly 
clear, and several steps in the spread of infection are strikingly 
reminiscent of our observations. First, L. monocytogenes that 
initially gain access to the bloodstream primarily accumulate 
in the liver (34). Neutrophils attracted by infl  ammatory sig-
nals enter the liver and become the major cell type initially 
involved in killing L. monocytogenes (34) because, at least in 
mice, L. monocytogenes are found to be adherent to the sur-
face of Kupff  er cells rather than inside them (34). Later, the 
bone marrow becomes a major reservoir for the bacteria, and 
there they grow within cells that have the same phenotype 
of the immature monocytes that acquire particles in the bone 
marrow (35). Any senescent neutrophils that home to the 
bone marrow (17) from the liver may harbor a few live rather 
than killed bacteria and effi   ciently transfer them to mono-
cytes in accordance with our observations. These monocytes, 
after entering the blood, act as Trojan horses to transport 
the bacteria to distal sites like the central nervous system (8, 
34–36), where they can cause meningitis. Our fi  ndings indi-
cate that bone marrow monocytes may pick phagocytic ma-
terial in the bone marrow routinely, so the fact that they pick 
up L. monocytogenes and transport it distally is not unique to 
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to a variety of other infections. Neutrophils also play an im-
portant role in serving as a medium for the cross-presentation 
of L. monocytogenes antigens by DCs (37), fi  tting with the 
possibility that some monocytes that took up neutrophils in 
the bone marrow carrying killed bacteria may have diff  eren-
tiated to DCs with the capacity to present these antigens to 
peripheral T cells.
Indeed, in our study, we found that monocytes were ca-
pable of processing and presenting antigens transferred from 
B cells and neutrophils. The presentation did not take place 
in the bone marrow, which is in contrast to presentation that 
occurs in response to splenic DCs that emigrate from the 
blood to the bone marrow (33). Instead, we found that after 
mobilizing from the bone marrow, monocytes express evi-
dence on their surface of having engulfed, processed, and 
presented epitopes from adoptively transferred B cells. The 
intensity of this MHC-II presentation increases when the 
monocytes are kept in culture for 2 d in the presence of GM-
CSF to promote their diff  erentiation toward DCs (32), indi-
cating that the monocytes retained a pool of foreign antigens 
intracellularly for presentation later as they augmented their 
phenotype and shifted toward DCs. T cell proliferation was 
detectable in vivo a few days after transferring bone marrow–
derived monocytes to the skin that had engulfed OVA-LX+ 
cells in the bone marrow before transfer. Some of these mon-
ocytes migrated from the skin to the draining lymph nodes, 
and T cell proliferation was induced. Thus, these data indi-
cate that the handling of antigen by monocytes does not mir-
ror the proteolytically destructive nature of macrophages 
toward engulfed antigens (21) such that when some mono-
cytes diff  erentiate to DCs a few days after leaving the bone 
marrow, they are able to “recall” previously engulfed anti-
gens for presentation.
MATERIALS AND METHODS
Mice. C57BL/6, congenic Ly5.1 (CD45.1) C57BL/6, BALB/c, and B 
cell–defi  cient μMT mice were purchased from The Jackson Laboratory. 
OT-II and MHC-II−/− mice were maintained in our colony. All mice were 
housed in a pathogen-free environment. All experiments were performed 
with age- and sex-matched animals at 6–12 wk of age in accordance with the 
Institutional Animal Care and Utilization Committee’s (Mount Sinai School 
of Medicine) approved protocols.
Labeling of blood monocytes. 0.5-μm FITC-conjugated (yellow gold) 
plain microspheres (2.5% solids [wt/vol]; Polysciences, Inc.) were diluted 
1:25 in PBS, and 250 μl of the solution was injected into the lateral tail 
vein for labeling of Gr-1lo monocytes. For labeling of Gr-1hi monocytes, 
250 μl of liposomes containing clodronate were i.v. injected followed by 
250 μl of fl  uorescent microspheres i.v. 16–18 h later. Clodronate was a gift 
from Roche and was incorporated into liposomes as previously described 
(27). We used the dose of CLL shown to fully eliminate blood monocytes 
(26); this method, with the introduction of CLL i.v., will also eliminate 
splenic and liver macrophages (27). Other macrophage populations are 
protected because CLL will not cross vascular barriers (27). In some exper-
iments, red fl  uorescent (580-nm excitation wavelength and 605-nm emis-
sion wavelength) carboxylate-modifi  ed 0.5-μm microspheres (2.0% solids 
[wt/vol]; Invitrogen) were used and conjugated to OVA (Sigma-Aldrich). 
Coupling of OVA to these particles was performed using the Carbo  diimide 
Kit from Polysciences, Inc.
Analysis of blood and tissues. Whole blood was drawn and subjected 
to red cell lysis using Pharmlyse (BD Biosciences), washed twice with 
DME containing 5 mM EDTA and 0.5% BSA, and stained with antibodies 
for FACS analysis. For fl  ow cytometric analysis of tissues, lymph nodes 
(brachial, axillary, cervical, popliteal, and inguinal) or spleen were dissoci-
ated into single-cell suspensions with collagenase D (Roche) for 30 min at 
37°C. Back skin was excised and digested using Liberase III (Roche) as de-
scribed previously (7). Bone marrow cells were obtained by fl  ushing the 
femur and tibia with HBSS containing 0.1% BSA and 5 mM EDTA fol-
lowed by red blood lysis and two washes in HBSS. For immunohisto-
chemistry, fresh tissues were frozen directly with Tissue Tek optimal 
cutting temperature (Sakura Finetek). Sections of 8-μm thickness were cut 
using a cryomicrotome (1900CM; Leica) and fi  xed with 3% paraformalde-
hyde on polylysine-coated slides.
Flow cytometry. Four-color staining for fl  ow cytometric analysis was con-
ducted using combinations of the following mAbs. All mAbs to the follow-
ing molecules were obtained from BD Biosciences except where otherwise 
indicated: F4/80 (Serotec), CD115 (eBioscience), CD4 (eBioscience), 
CD11c (eBioscience), CD45.1 (eBioscience), CD45.2 (eBioscience), anti-
FITC (Jackson ImmunoResearch Laboratories), Gr-1, CD11b, IAb, B220, 
CD19, NK1.1, DX5, CD8, CD3, CD62L, mouse IgG1, rat IgG2a, and 
hamster IgG isotype controls. Biotinylated annexin V (Sigma-Aldrich) was 
used to identify apoptotic cells followed by streptavidin-APC (Caltag) incu-
bation. Flow cytometric analysis was performed on a FACScalibur (BD Bio-
sciences) and analyzed with FlowJo software (Tree Star).
Immunohistochemistry. Immunofl   uorescence microscopy was per-
formed using biotin-conjugated CD11b or rat IgG (BD Biosciences) and 
streptavidin-Cy3 (Sigma-Aldrich). Slides were mounted with Vectashield 
containing DAPI (Vector Laboratories). Images were acquired using a 
fl   uorescence microscope (DMRA2; Leica) and a digital CCD camera 
(model ORCA-ER; Hamamatsu) and were analyzed using Openlab soft-
ware (Improvision).
Blockage of cell homing to bone marrow. Mice were injected i.v. with 
LX particles followed by CLL 8–10 h later. At the time of liposome injec-
tion, mice received either PBS or 400 ng PT i.v. (List Biological Labora-
tories). PT, an exotoxin produced by Bordetella pertussis, blocks the 
signaling through Gi protein–coupled receptors by mediating adenosine di-
phosphate ribosylation of their α subunits (38, 39). Results were analyzed 
after 16 h. To ensure that PT did not impair the phagocytic capacity of 
monocytes, mice received either PBS or 400 ng PT i.v. followed by 250 μl 
of 0.5-μm LX beads (diluted 1:25) i.v. 2 h later (as described for Gr-1lo 
monocyte labeling). Blood, spleen, and bone marrow cells were analyzed 4 
and 24 h thereafter.
Adoptive transfer of LX+ B cells and neutrophils. To label B cells with 
LX microspheres, C57BL/6 mice were injected with 250 μl CLL i.v. fol-
lowed by 250 μl of 0.5-μm LX beads diluted 1:25 i.v. 18 h later (as de-
scribed for Gr-1hi monocyte labeling). 4 h later, CD45.2+ B cells were 
isolated from the spleen by positive magnetic cell separation using anti-B220 
microbeads (Miltenyi Biotec) with a purity of 95–98%, and 15–20% of these 
cells were LX+. 10 million cells were injected into monocyte-depleted (18 h 
after clodronate liposomes i.v.) CD45.1+ mice corresponding to  1.5–2 × 
106 LX+ B cells per recipient mouse.
For ex vivo labeling of neutrophils, bone marrow was fl  ushed from 
CD45.2+ mice, washed, and whole bone marrow cells were incubated with 
LX beads in RPMI-1640 containing 50% FBS at 37°C for 1 h. The majority 
of isolated bone marrow cells were neutrophils (17), and 75% of the LX+ 
cells were neutrophils. 27 million of these cells were injected into mono-
cyte-depleted (18 h after the administration of CLL i.v.) CD45.1+ mice, 
corresponding to 6 × 106 LX+ cells per animal. The neutrophil phenotype 
was confi  rmed by staining for CD11b and Gr-1 and typical multilobulated 
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Analysis of antigen presentation. BALB/c B cells were isolated from 
spleen and lymph nodes by positive magnetic cell separation using B220 mi-
crobeads (Miltenyi Biotec) with a purity of 95–98%. 5 × 106 B220+ BALB/c 
cells were injected i.v. per mouse into clodronate liposome–treated C57BL/6 
mice 18 h after liposome injection. Blood cells of recipient mice were ana-
lyzed 1 or 3 d after B cell transfer. To directly assess antigen presentation, we 
used biotin-conjugated Y-Ae antibody that recognizes I-Eα 56–73 peptide 
from BALB/c donor cells in the context of C57BL/6 recipient I-Ab mole-
cules (31). Streptavidin-APC (Caltag) was used for detection. Blood mono-
cytes were obtained 3 d after BALB/c B cell transfer or from untreated 
controls and were cultured for 2 d in RPMI-1640 with 10% FBS, penicil-
lin/streptomycin, and 5 × 10−5 M β-mercaptoethanol. The cultures were 
supplemented with GM-CSF contained in the supernatant of J5587 cells to 
promote diff  erentiation toward a DC phenotype as described previously 
(32). I-Ad staining (BD Biosciences) was used to monitor the presence of live 
BALB/c B cells (100% positive).
T cell proliferation assays. CD4+ T cells were isolated from spleen and 
lymph nodes of OT-II mice using CD4 microbeads (Miltenyi Biotec). 
OT-II cells were labeled with 5-CFSE (Invitrogen) by incubation with 
5 μM CFSE in RPMI-1640 for 10 min, and 1–2 × 106 CD4+ CFSE+ 
OT-II cells were injected per animal. C57BL/6 WT or μMT mice received 
i.v. either plain red fl  uorescent beads or red fl  uorescent OVA-coupled beads. 
Some of these mice received CLLs 18 h before LX was administered. 1 d 
later, CD4+ CFSE+ OT-II cells were injected i.v., and T cell proliferation 
monitored by CFSE dye dilution was analyzed 3 d later in blood, lymph 
nodes, spleen, and bone marrow.
Adoptive monocyte transfer to test T cell proliferation. To label 
monocytes with OVA-coupled particles, C57BL/6 mice were injected with 
red fl  uorescent OVA-coupled beads and with CLL 8 h later. 16 h thereafter, 
mice were killed, and bone marrow monocytes were isolated by positive 
magnetic cell separation using biotin-conjugated CD115 (eBioscience) fol-
lowed by streptavidin-coupled microbeads (Miltenyi Biotec), yielding a pu-
rity of 95–98%. 15–30% of the isolated monocytes also carried microspheres. 
To exclude cross-presentation of dying monocytes after adoptive transfer, 
the recipients of adoptively transferred monocytes were MHC-II−/− mice. 
T cells were isolated from spleen and lymph nodes of OT-II mice, labeled 
with CFSE ex vivo, and injected i.v. (10 × 106 total cells per animal, corre-
sponding to 1–2 × 106 CD4+ CFSE+ cells) into MHC-II−/− mice. 1 d later, 
3–5 × 106 bone marrow monocytes or 6–10 × 106 OVA-loaded spleen 
DCs used as a positive control were intradermally injected into the shaved 
back skin and front footpad (25, 32). Mice were killed after 3 or 6 d; lymph 
nodes, spleen, blood, and skin were analyzed for the presence of particle-
bearing cells and T cell proliferation (CFSE dye dilution).
Online supplemental material. Fig. S1 shows that beads administered i.v. 
are acquired almost in total by cells and that few free beads remain in the 
blood or enter the bone marrow. Online supplemental material is available 
at http://www.jem.org/cgi/content/full/jem.20052119/DC1.
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